Pyrrolopyrimidine compounds and their uses
The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.
1. A method for the treatment of cancer by inhibiting of a cyclin-dependent kinase (CDK) comprising administration of an effective amount of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide or a pharmaceutically acceptable salt thereof to a subject in need of treatment thereof.
2. The method according to claim 1 wherein the cancer is carcinoma of the bladder, breast, colon, kidney, epidermis, liver, lung, oesophagus, gall bladder, ovary, pancreas, stomach, cervix, thyroid, nose, head and neck, prostate, or skin; a hematopoietic tumour of lymphoid lineage; a hematopoietic tumour of myeloid lineage; thyroid follicular cancer; a tumour of mesenchymal origin; a tumour of the central or peripheral nervous system; melanoma; seminoma; teratocarcinoma; osteosarcoma; xeroderma pigmentosum; keratoctanthoma; thyroid follicular cancer; or Kaposi's sarcoma.
3. The method according to claim 2 wherein the wherein the hematopoietic tumour of lymphoid lineage is leukemia, acute lymphocytic leukemia, chronic lymphocytic leukaemia, B-cell lymphoma, T-cell lymphoma, multiple myeloma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma, or Burkett's lymphoma.
4. The method according to claim 2 wherein the tumour of the central or peripheral nervous system is astrocytoma, neuroblastoma, glioma or schwannoma.
5. The method according to claim 4 wherein the tumour of the central or peripheral nervous system is neuroblastoma.
6. The method according to claim 2 wherein the cancer is carcinoma of the breast.
7. The method according to claim 2 wherein the cancer is melanoma.
8. The method according to claim 2 wherein the cancer is a tumour of mesenchymal origin.
9. The method according to claim 1 wherein the cancer is breast cancer, ovarian cancer, colon cancer, prostate cancer, oesophageal cancer, squamous cancer and non-small cell lung carcinomas.
10. The method according to claim 1 wherein the cancer is breast cancer, pancreatic cancer, colorectal cancer, lung cancer, sarcoma, leukemia, glioma, familial melanoma or melanoma.
11. The method according to claim 1 wherein the cancer is small cell lung cancer, non-small cell lung cancer, pancreatic cancer, breast cancer, glioblastoma multiforme, T cell ALL and mantle cell lymphoma.
12. The method according to claim 1 wherein the cancer is breast cancer, pancreatic cancer, colorectal cancer, lung cancer or melanoma.
13. The method according to claim 12 wherein the cancer is pancreatic cancer.
14. The method according to claim 12 wherein the cancer is colorectal cancer.
15. The method according to claim 9 wherein the cancer is prostate cancer.
16. The method according to claim 11 wherein the cancer is non-small cell lung cancer.
17. The method according to claim 1 wherein the cancer is mantle cell lymphoma.